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Interleukin-33 (IL-33) is a nuclear-associated cytokine of the IL-1 family originally described as a potent
inducer of allergic type 2 immunity. IL-33 signals via the receptor ST2, which is highly expressed on group
2 innate lymphoid cells (ILC2s) and T helper 2 (Th2) cells, thus underpinning its association with helminth
infection and allergic pathology. Recent studies have revealed ST2 expression on subsets of regulatory
T cells, and for a role for IL-33 in tissue homeostasis and repair that suggests previously unrecognized inter-
actions within these cellular networks. IL-33 can participate in pathologic fibrotic reactions, or, in the setting
of microbial invasion, can cooperate with inflammatory cytokines to promote responses by cytotoxic NK
cells, Th1 cells, and CD8+ T cells. Here, we highlight the regulation and function of IL-33 and ST2 and review
their roles in homeostasis, damage, and inflammation, suggesting a conceptual framework for future studies.Introduction
In 1989, a primary response gene was identified in serum-stim-
ulated fibroblasts that resembled the extracellular portion of
the interleukin-1 (IL-1) receptor. This protein, named T1 (Were-
nskiold et al., 1989), ST2 (Tominaga, 1989), Der4 (Lanahan
et al., 1992), or Fit1 (Bergers et al., 1994), was the soluble form
of the IL-33 receptor. Now designated IL-1-receptor-like 1
(IL1RL1), we will here use the common designation ST2. The
ligand for ST2was identified in 2005 during a search for unknown
IL-1 family members (Schmitz et al., 2005), which revealed a
sequence originally identified as a canine gene induced in endo-
thelial cells in response to subarachnoid hemorrhage (Onda
et al., 1999). T helper 2 (Th2) cells and mast cells expressed
ST2, and IL-33 promoted Th2-associated allergic immunity
when administered to mice (Coyle et al., 1999; Lo¨hning et al.,
1998; Schmitz et al., 2005; Townsend et al., 2000; Xu et al.,
1998; Yanagisawa et al., 1997). Although IL-33 ismost frequently
characterized as an epithelial cytokine that promotes type 2 im-
mune responses, recent studies have extended its biology to
include roles in basal tissue regulation, organ-specific injury
and repair (which promote fibrosis when dysregulated), and
immunity to viruses, microbes, and neoplasms. Despite this
pleiotropic spectrum, surprising gaps remain in our knowledge
regarding the molecular control and diverse functionalities of
this cytokine. Here, we review the literature and propose a pro-
gressivemodel for conceptualizing the role of IL-33 in homeosta-
sis and inflammation. In the homeostatic stage, constitutive
pools of IL-33 become active locally to sustain basal physiology
by activating ST2+ resident cells in a cell- and tissue-specific
manner. In the amplification stage, tissue-specific pools of
IL-33 increase and ST2+ cells increase in numbers in attempting
to maintain homeostasis, usually in response to perturbations
like parasites or allergens and resulting in overt manifestations
of type 2 immunity. When continued over long periods, patho-
logic fibrosis can occur. In the conversion stage, inflammationfrom damaged tissues leads to the acquisition of IL-33 respon-
siveness through induced expression of ST2 on inflammatory
cells, including NK cells, Th1 cells, and CD8+ T cells, and result-
ing in overt manifestations of type 1 immunity. This facilitates
clearance of pathogens but often at the cost of tissue damage.
Consideration of this model might have implications in consid-
ering therapeutic strategies for altering IL-33 activities in vivo.
Molecular Characterization of IL-33
IL-33 is a member of the IL-1 family, which includes IL-1a, IL-1b,
IL-18, IL-36a, IL-36b, IL-36g, and IL-37, and the receptor antag-
onists IL-1Ra, IL-36Ra, and possibly IL-38 (Garlanda et al.,
2013a). IL-33 is localized in the cell nucleus but also functions
as a cell-free cytokine (Carriere et al., 2007), and in this way is
similar to IL-1a and HMGB1 (Garlanda et al., 2013a; Moussion
et al., 2008). Human and mouse IL33 consist of seven coding
exons, which produce a 31 kDa protein of 270 and 266
amino acids, respectively. Exons 1–3 encode the N-terminal do-
mains required for IL-33 nuclear localization, whereas exons 4–7
encode the C-terminal IL-1-like cytokine domain (Carriere et al.,
2007). The nuclear localization domain (amino acids 1–65 in hu-
man) includes a chromatin-binding motif (amino acids 40–58)
(Roussel et al., 2008), which mediates interaction of IL-33 with
histone dimers and promotes chromatin compaction; mutation
at R48 results in diffuse cytoplasmic localization of IL-33 and
abolishes IL-33-mediated transcriptional repression in Gal4 re-
porter assays (Roussel et al., 2008). IL-33 has also been shown
to bind the p65 subunit of NF-kB via the RelA interaction domain
(amino acids 66–111) and inhibit NF-kB transcriptional activity in
HEK293RI cells (Ali et al., 2011). Despite these data, evidence
that nuclear IL-33 regulates normal transcriptional activity as
part of its functionality requires further study.
The remainder of the IL-33 protein (amino acids 109–266 in
mouse) encodes the IL-1-like cytokine domain, a 12-stranded
b-trefoil fold similar to IL-1a, IL-1b, IL-1Ra, and IL-18 (LingelImmunity 42, June 16, 2015 ª2015 Elsevier Inc. 1005
Figure 1. IL33-ST2 Molecular
Characteristics
IL-33 is transcribed from seven coding exons
and transported to the nucleus. During lytic
cell death associated with necrosis or nec-
roptosis, or possibly via direct secretion from
intact cells, full-length IL-33 is released from
the nucleus into the extracellular environment.
Activation of apoptotic pathways leads to
inactivation of IL-33 via caspase 3- or 7-
mediated cleavage. Once released, full-length
IL-33 can be further processed by serine
proteases, such as cathepsin-G and elastase,
into forms with increased activity. The IL-33
receptor ST2 is produced in two forms, a
short soluble (sST2) or longer membrane-
bound form (ST2L). sST2 is constitutively ex-
pressed, but can be induced during tissue
damage, and binds IL-33 and restricts
its availability. In contrast, both full-length and actively processed IL-33 bind to ST2L in combination with IL-1RAcP on target cells and induce
canonical NF-kB and MAPK signaling pathways leading to cellular activation and proliferation.
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facilitating recruitment of IL-1RAcP to form the heterotrimeric
signaling complex. Unlike IL-1b and IL-18, the N-terminal portion
of IL-33 does not require cleavage by caspase 1 for release from
the cell or to initiate signaling via ST2 (Cayrol and Girard, 2009;
Lu¨thi et al., 2009; Talabot-Ayer et al., 2009). Apoptosis-associ-
ated caspase-3 and caspase-7 cleave and inactivate IL-33 at a
conserved residue, Asp178 (Asp175 in mouse), within the IL-1-
like domain (Cayrol and Girard, 2009; Lu¨thi et al., 2009). N-termi-
nal processing of full-length IL-33 can also occur via a short
stretch of amino acids between the nuclear-binding domain
and the IL-1-like cytokine domain. These residues are targeted
by extracellular proteases common at inflammatory sites,
including neutrophil cathepsin G, neutrophil elastase and mast
cell serine proteases, resulting in IL-3395–270, IL-3399–270, and
IL-33109–270. The resulting 19 kDa cytokine forms of IL-33 exhibit
10- to 30-fold higher bioactivity, and are functionally similar to
the 18 kDa recombinant IL-33112–270 available commercially (Le-
franc¸ais and Cayrol, 2012; Lefranc¸ais et al., 2014; 2012). The
relative contributions of full-length and cleaved IL-33 in vivo
are incompletely resolved.
Whether or not it is necessary for underlying function, the nu-
clear localization of full-length IL-33 is highly regulated, sincemis-
localization has drastic consequences. Gene-targeted knockin
mice in which the IL33 nuclear domain was replaced by dsRed
reporter sequence express a fusion protein consisting of the cyto-
kine domain but lacking nuclear localization. Heterozygous mice
are born normally but develop high serum IL-33 and lethal inflam-
mation characterized by splenomegaly with multi-organ infiltra-
tion by myeloid cells, particularly eosinophils, neutrophils, and
monocytes and/ormacrophages (Bessa et al., 2014). These path-
ologic changes resemble those induced by constitutive overex-
pression of full-length IL-33 (Talabot-Ayer et al., 2015).
Regulation of IL33 mRNA is also not well understood. In the
mouse, IL-33 transcription initiates from one of two non-coding
exons which are associated with constitutive or induced produc-
tion of IL-33 (Polumuri et al., 2012; Talabot-Ayer et al., 2012).
There are also a number of potential high-quality miRNA binding
sites within the long 30 UTR of IL33 (http://www.microrna.org;
A.S., unpublished data). Among these, miR-9, miR-145, miR-
214, and miR-499-5p have been linked to vascular and coronary1006 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.function (Gidlo¨f et al., 2013; Hu et al., 2014; Jin et al., 2015; Shi-
mizu et al., 2013; Turczynska et al., 2012; Wang et al., 2010) and
could be of interest because IL-33 from cardiac fibroblasts can
promote cardioprotection (Sanada et al., 2007).
IL-33 Release and/or Secretion
Because IL-33 lacks a traditional signal sequence (Garlanda
et al., 2013a) or a non-canonical processing and export pathway,
cell death by necrosis and/or active necroptosis might be domi-
nant mechanisms by which the cytokine reaches the extracel-
lular milieu (Cayrol and Girard, 2014; Kaczmarek et al., 2013),
leading to its designation as an ‘‘alarmin.’’ Indeed, receptor-in-
teracting protein kinase 1 (Ripk1) knockout mice succumb to
perinatal necroptosis-driven inflammation and exhibit marked in-
creases in extracellular IL-33 (Rickard et al., 2014). However, it is
unclear whether cell death can account entirely for the biologic
effects of IL-33. IL-33 release from living cells was reported in hu-
man bronchial epithelium exposed to Alternaria (Kouzaki et al.,
2011) and from mechanically-stressed fibroblasts in vitro and
in vivo (Kakkar et al., 2012). Several studies suggest extracellular
ATP can promote IL-33 production or secretion in models of
allergic inflammation (Byers et al., 2013; Hudson et al., 2008;
Kouzaki et al., 2011). Human IL33 transcripts lacking exon 3, 4,
and/or 5 have been recovered from cell lines and primary cells
(Hong et al., 2011; Tsuda et al., 2012). However, these splice
forms appear to be minor components in primary cells and
further work is required to determine their physiologic relevance.
Other nuclear alarmins such as HMGB1 and IL-1amight be use-
ful in understanding IL-33 regulation and activity. HMGB1 is
ubiquitously expressed and, while it can be liberated from the
cell by necrosis, active release from inflammatory macrophages
may constitute an additional release mechanism (Harris et al.,
2012). In contrast, IL-1a appears to require necrosis to access
the extracellular space (Rider et al., 2013). Further study is
necessary to elucidate these various pathways and how they
are controlled.
The IL-33 Receptor Subunit ST2
The receptor complex for IL-33 consists of the specific subunit
ST2 and the shared signaling chain, IL-1RAcP (Figure 1).
IL1RL1 (ST2) is in a conserved locus on human chromosome 2
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those for IL-1 (IL1R1, decoy receptor IL1R2), IL-18 (IL18R1, IL18-
RAP), and IL-36 (IL1RL2) (Garlanda et al., 2013a). IL-1 family re-
ceptors are present throughout vertebrates together with their
cytokine ligands, suggesting their co-evolutionary development.
Although ST2 exhibits a similar distribution, its ligand IL-33
apparently arose later in evolution, because it is present in mam-
mals but absent in non-mammalian vertebrates (Sattler et al.,
2013). Despite this disconnect, there is no evidence for uniden-
tified ST2 ligands in humans or mice. Further, ST2 is the only
well-documented receptor for IL-33. In support of this, mice
with loss of IL-33 nuclear localization signals or constitutive over-
expression of IL-33 develop systemic inflammation that is abro-
gated by crossing onto the ST2-deficient background (Bessa
et al., 2014; Talabot-Ayer et al., 2015).
Soluble ST2
An additional layer of complexity in the biology of IL-33 is the
occurrence of two ST2 isoforms, ST2L and sST2 (Yanagisawa
et al., 1993). ST2L is the full-length protein and includes the
extracellular immunoglobulin (Ig)-like domains, a short extracel-
lular spacer, the transmembrane domain, and an intracellular TIR
domain (Liu et al., 2013). sST2 is a short form that lacks the final
three exons, resulting in a soluble secreted protein consisting
of the extracellular cytokine-binding domains. sST2 is present
constitutively in human serum (Kuroiwa et al., 2000; Oshikawa
et al., 2001), where it acts as a decoy receptor by binding free
IL-33. sST2 is increased by diverse inflammatory stimuli and
in cardiovascular, rheumatologic, and allergic diseases, poten-
tially restricting the deleterious effects of elevated systemic
IL-33 (Hayakawa et al., 2007; Kumar et al., 1997; Oshikawa
et al., 2002; Weinberg et al., 2002; Yanagisawa et al., 1993). In
humans, genome-wide association studies (GWASs) have iden-
tified IL1RL1 variants associated with altered levels of serum
sST2 (Ho et al., 2013), which could influence susceptibility to
IL-33-mediated responses.
ST2L Signaling
The crystal structure of the ectodomain of ST2 complexed with
IL-33 has been solved (Liu et al., 2013). The ectodomain of
ST2 consists of 3 Ig-like domains and resembles IL-1R1. The
two distal domains (D1D2) pack together and connect via a flex-
ible linker to the membrane-proximal third (D3) domain; IL-33
binds between the D1D2 and D3 domains (Liu et al., 2013).
The binary IL-33-ST2 complex recruits IL-1RAcP, a shared
signaling component of receptors for IL-1a and IL-1b, and IL-
36a, IL-36b, and IL-36g, to initiate signaling. IL-1RAcP signaling
induces recruitment to the receptor complex of MyD88, IRAK,
IRAK4, and TRAF6; activation of MAP kinases Erk1/2, p38, and
JNK; activation of AP-1 transcription factors; and degradation
of IkBa leading to translocation of NF-kB to the nucleus (Andrade
et al., 2011; Schmitz et al., 2005). IL-33 signaling might also
require JAK2 activation (Funakoshi-Tago et al., 2011). As these
signaling pathways are largely conserved with TLR, IL-1, and
IL-18 signaling, the unique biologic effects of IL-33 are likely
mediated by ST2L expression. ST2L signaling pathways can
be inhibited by the IL-1 receptor-like molecule SIGIRR (TIR8),
such that in Th2 cells, SIGIRR negatively regulates ST2 signaling
and inhibits type 2 inflammatory processes (Bulek et al., 2009).IL-23 signaling impairs IL-33-mediated signaling in intestinal
Tregs by restricting phosphorylation and activation of the Th2-
associated transcription factor GATA3 (Schiering et al., 2014).
IFN-g potently inhibits IL-33 activation of ILC2 in vitro and in vivo
and might be critical in suppressing this pathway during infec-
tions by bacteria and viruses (see below; Molofsky et al.,
2015). Whether other described inhibitors of MyD88-dependent
pathways, such as A20 (TNFAIP3), IRAK-M, or SOCS family
members restrict IL-33/ST2 signaling is unknown (Garlanda
et al., 2013b; Tamiya et al., 2011; Turer et al., 2008). The regula-
tion, interaction, and signaling of IL-33 and ST2 are summarized
in Figure 1.
Sources and Production of IL-33
IL-33 protein is constitutively present in healthy mice and hu-
mans, primarily in nuclei of non-hematopoietic cells (Schmitz
et al., 2005), with particular abundance in specialized popula-
tions of epithelial and endothelial cells (Moussion et al., 2008;
Pichery et al., 2012). IL-33 was first identified in human lymph
node high endothelial venules (HEV; originally named NF-HEV
or DVS-27) and its expression was induced in canine cerebral
vasculature after subarachnoid hemorrhage (Baekkevold et al.,
2003; Onda et al., 1999). IL-33 is highly expressed in lymph
node and spleen fibroblastic reticular cells (FRC) in mice and hu-
mans, although not inmouseHEV (Moussion et al., 2008; Pichery
et al., 2012). In contrast to humans, mouse endothelial expres-
sion of IL-33 appears restricted to adipose tissue, liver, and
female reproductive tract (Carlock et al., 2014; Marvie et al.,
2010; Pichery et al., 2012). IL-33 expression in endothelial cells
in vitro has been linked to cellular quiescence and confluence,
and might require Notch signals (Ku¨chler et al., 2008; Sundlisa-
eter et al., 2012). Human and mouse share constitutive IL-33
expression at epithelial surfaces, including in skin, stomach, in-
testine, salivary gland, vagina, and lung, where expression is
particularly high in alveolar type 2 cells (R.M.L., unpublished
data; Moussion et al., 2008; Pastorelli et al., 2010; Schmitz
et al., 2005); species-specific differences might exist (Sundnes
et al., 2015). This epithelial expression pattern partially overlaps
with other cytokines that target ILC2s, including TSLP and IL-25,
suggesting potentially shared functions (Bulek et al., 2010;
R.M.L., unpublished data). During inflammation additional popu-
lations express IL-33, such as epithelial progenitor cells in
models of COPD (Byers et al., 2013). In myeloid cells, Il33 tran-
scription can be induced by allergic challenge (Hardman et al.,
2013) and TLR signaling. Mouse peritoneal macrophages ex-
press Il33 mRNA in response to TLR activation by a process
dependent on TBK1, RIG-I, and IRF3 (Polumuri et al., 2012).
TLR2-dependent induction of Il33 mRNA in human monocytes
and mouse macrophages was dependent on TRAF6 and IRF7
(Sun et al., 2014). Experimental demonstration of pathways
that induce IL-33 protein in hematopoietic cells in vivo, as
well as the physiologic relevance of hematopoietic sources of
IL-33, require further study.
IL-33 in Tissue Homeostasis
IL-33 expression is regulated by diverse stimuli and in a cell- and
tissue-specific manner, reflecting interactions in tissue between
constitutive and induced components. Here, it might be useful
to consider cell types that constitutively express high amountsImmunity 42, June 16, 2015 ª2015 Elsevier Inc. 1007
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initial responses to IL-33. Non-hematopoietic cells, including
endothelial cells, epithelial cells and fibroblasts, are reported to
express ST2L and respond to IL-33, although the in vivo conse-
quences of signaling in these populations are not well described.
In hematopoietic cells, IL-33 acts primarily on immune cells asso-
ciated with type 2 and regulatory immune responses, including
ILC2s, Th2 cells, eosinophils, mast cells, and basophils, as well
as subsets of dendritic cells, myeloid-derived suppressor cells,
and Tregs (Cayrol and Girard, 2014). ILC2s, some Tregs, and
mast cells are the primary tissue-resident cells that constitutively
express high levels of ST2, positioning these cells as initial targets
of IL-33. Mast cells are present in most tissues, can be activated
by IL-33 to release mediators (Lunderius-Andersson et al., 2012),
and might interact with ILC2s to maintain epithelial integrity (Roe-
diger et al., 2013). ILC2s are systemically distributed in tissues,
including skin, lung, gastrointestinal tract, uterus, and adipose
tissue. When activated, they comprise the major innate source
of type 2 cytokines such as IL-5, IL-13, IL-9, andGM-CSF, in addi-
tion to epithelial growth factors such as amphiregulin (Cheng and
Locksley, 2015; vonMoltke and Locksley, 2014;Moro et al., 2010;
Neill et al., 2010; Price et al., 2010). Studies comparing responses
to IL-33 in ILC2-replete Rag-knockout and ILC2-deficient Rag-
Il2rg- double knockout mice suggest that ILC2s comprise the
major innate target of exogenous IL-33 (Brestoff et al., 2014;
McHedlidze et al., 2013; Moro et al., 2010). IL-33-mediated
ILC2 activation typically leads to tissue accumulation of eosino-
phils and alternatively activated macrophages (AAM) and is asso-
ciated with elevated numbers of tissue Tregs.
Certain subsets of Tregs, including those in adipose tissue, ex-
press high amounts of the Th2-associated transcription factor
GATA3, as well as ST2, and require IL-33 for their maintenance
and function (Molofsky et al., 2015; Schiering et al., 2014; Vasan-
thakumar et al., 2015). These tissue Tregs are highly suppressive
and express IL-10 together with other markers associated with
activation, including ICOS, KLRG1, and GITR. In vitro, IL-33 pro-
motes proliferation of ST2+ Tregs and further enhances GATA3
expression, which stabilizes FoxP3 expression while increasing
ST2 expression in a feed-forward reinforcing manner (Schiering
et al., 2014; Vasanthakumar et al., 2015). Although IL-33 has
direct effects on Treg stabilization and function, IL-33 also pro-
motes ILC2 and/or dendritic cell subsets that enhance Treg
numbers and function by indirect mechanisms (Besnard et al.,
2015; Duan et al., 2012; Matta et al., 2014; Molofsky et al.,
2015). Tregs generated during the perinatal period express
ST2 and are highly suppressive and proliferative (Yang et al.,
2015). These perinatal Tregs restrict the tissue autoimmune
manifestations of Aire deficiency, a model of the human autoim-
mune disorder, APECED (autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy), hinting at a possible role
for IL-33 in supporting perinatal tissue tolerance.
Although further work is needed, these data suggest a model
whereby ILC2s, a subset of Tregs, and possibly mast cells are
positioned in tissues through a developmentally regulated pro-
cess, where they can respond to local fluctuations in extracel-
lular IL-33. In certain tissues, additional resident hematopoietic
or tissue cells might also respond to IL-33, although this remains
poorly explored. Serum sST2 serves to localize endogenous
IL-33, where it might mediate processes involved in normal1008 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.growth and development while sustaining tolerance by the
developing adaptive immune system (Figure 2A).
Adipose Tissue
The best-studied model of IL-33 function in tissue homeostasis
is in white adipose tissue (WAT) (Figure 2). White adipose tissue
is the major storage site for high-energy triglycerides, which are
released as free fatty acids by lipolysis during periods of energy
need. WAT of lean mice is populated with ST2+ ILC2s and Tregs
that promote WAT eosinophils and AAM (Brestoff and Artis,
2015; Hams et al., 2013; Mathis, 2013; Molofsky et al., 2013b;
Moro et al., 2010). IL-33 is abundant in adipose tissue, where
expression has been confirmed in endothelial cells and fibro-
blast-like reticular cells, although further study is needed (Kolo-
din et al., 2015; Molofsky et al., 2015; Pichery et al., 2012;
Wood et al., 2009; Zeyda et al., 2013). In mice, loss of IL-33 or
ST2 leads toworsening obesity and insulin resistance, a hallmark
of type 2 diabetes (Brestoff et al., 2014; Lee et al., 2015; Miller
et al., 2010; Vasanthakumar et al., 2015). These changes are
associated with a shift in the function and population of normal
WAT immune cells, characterized by diminished ILC2 activation
and decreased numbers of eosinophils, AAM, and Tregs (Kolo-
din et al., 2015; Molofsky et al., 2015; Vasanthakumar et al.,
2015). Each of these cell types has been shown to protect in
mouse models of obesity-induced insulin resistance (Brestoff
and Artis, 2015; Mathis, 2013; Wu et al., 2011), supporting the
concept whereby IL-33 sustains the architecture and function
of ST2+ resident cells that limit infiltration of adipose tissue by in-
flammatory lymphocytes and myeloid cells that lead to insulin
resistance and metabolic syndrome.
Although WAT is responsible for lipid storage, brown adipose
tissue (BAT) expresses high amounts of uncoupling protein 1
(UCP1) and converts energy into heat, an important component
of cold adaptation. BAT is abundant in newborns and decreases
in adults (Frontini and Cinti, 2010). Recent studies have shown
that white adipose tissue can convert to a brown-like depot,
termed ‘‘beige’’ or ‘‘brite’’ adipose (Bartelt and Heeren, 2014;
HarmsandSeale, 2013). This occurspredominantly in subcutane-
ousWATdepots andmight facilitateBAT-mediatedadaptive ther-
mogenesis (Bartelt and Heeren, 2014; Harms and Seale, 2013).
Both BAT and beige adipose dissipate energy and influence
glucose and VLDL-triglyceride metabolism (Bartelt et al., 2011;
Chondronikola et al., 2014), potentially protecting against meta-
bolic disorders such as type 2 diabetes. Type 2 immune cells
have been implicated in promoting cold-induced adipose tissue
beiging (Brestoff and Artis, 2015; Qiu et al., 2014; Rao et al.,
2014), and IL-33 can act on ILC2s to promote beiging even at
room temperature (Brestoff et al., 2014; Lee et al., 2015). In one
study, ILC2-derived IL-13 was shown to act on adipose precur-
sors to promote a beige fate (Lee et al., 2015), whereas a second
studydemonstrated ILC2s inducebeigingbysecreting theendog-
enousopioidmethionine-enkephalin (Brestoff et al., 2014). Funda-
mental questions remain, including the relevant source(s) and
direct target(s) of adipose tissue IL-33 and the signals and mech-
anisms that promote adipose tissue IL-33 production and release.
Female Reproductive Tissues
IL-33 and ST2 are expressed in uterine endometrial cells and in-
crease with decidualization before fetal implantation (Salker
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Figure 2. Progressive Stages of IL-33-ST2
(A) Homeostasis. IL-33 is present in the nuclei of a subset of epithelial
and endothelial cells at rest. Poorly understood signals promote
IL-33 release or focal cellular necrosis. IL-33 acts on tissue-resident
ST2-expressing ILC2, Treg, and possibly mast cells, inducing the
production of IL-5, IL-13, IL-10, amphiregulin (Areg), and other sig-
nals that promote eosinophils and alternatively activated macro-
phages (AAM). These cells and signals feed back on the tissue and
might regulate remodeling and limit inflammation, in part by acti-
vating tissue progenitor cells. sST2 in the blood prevents systemic
IL-33 effects.
(B) Amplification. During tissue allergic insults and injury, epithelial
and endothelial cells release IL-33, likely via necrosis, and IL-33
expression is further induced. Increased extracellular IL-33 activates
and expands tissue ILC2 and Treg, and promotes recruitment and
survival of additional immune cells (eosinophils, AAM, Th2 cells,
basophils). These cells and signals feed back on the tissue to pro-
mote remodeling and limit inflammation, in part by activating tissue
progenitor cells. In acute injury (infarction, tissue damage, helminth
infection) these pathways help resolve injury and limit helminth
infection. Chronic stimuli, such as allergens and repetitive tissue
damage, lead to multiple cycles of IL-33 release that promote
chronic allergic pathology, tissue fibrosis, increased Th2 cells, loss of
Treg and other regulatory components, and increased tissue stores
of IL-33. sST2 production is increased, but IL-33 concentrations
might exceed blood buffering capacity in chronic damage and lead
to systemic effects.
(C) Conversion. Infectious or inflammatory triggers elicit tissue
damage and epithelial breaches in the context of pathogen-associ-
ated molecular patterns. Pre-formed tissue IL-33 stores are
released, likely via necrosis, and IL-33 is further induced in tissue
cells. Inflammation and foreign antigen induces dendritic cell acti-
vation and IL-12 production, trafficking of inflammatory leukocytes
from blood, and increased responsiveness to IL-33 through upre-
gulation of ST2 on additional cell types. Activated inflammatory cells
and cytokines, including IFN-g, repress the Treg and type 2 immune
response and facilitate killing of microbial and viral pathogens. In
chronic inflammatory states, such as COPD and possibly autoim-
mune disease, IL-33 pools are increased and promote repetitive
cycles of IL-33 release, increasing tissue damage. sST2 production
is increased, but IL-33 levels might exceed blood buffering capacity
in chronic damage and lead to systemic effects.
Immunity 42, June 16, 2015 ª2015 Elsevier Inc. 1009
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Reviewet al., 2012). IL-33 was reported in placental macrophages and
shown to promote the growth of trophoblasts (Fock et al.,
2013). Ovarian IL-33 and ST2 increase with ovulation (Carlock
et al., 2014), where IL-33 is expressed by endothelial cells sur-
rounding developing follicles (Wu et al., 2015). IL-33 is required
for recruitment of macrophages to mediate ovarian atresia
post-ovulation, and IL-33-deficient mice show a 33% reduction
in reproductive lifespan (Wu et al., 2015). These findings suggest
that IL-33 might promote the physiologic clearance of atretic
ovarian follicles and possibly promote uterine and placental re-
modeling in the course of the estrous cycle and pregnancy.
ILC2s are present in the uterus (Nussbaum et al., 2013), where
they might coordinate aspects of the IL-33 response.
In the mammary gland, cells and cytokines associated with
type 2 immunity mediate ductal branching and outgrowth during
pubescent morphogenesis (Gjorevski and Nelson, 2011; Khaled
et al., 2007; Sternlicht et al., 2006), a process that occurs within
an adipose tissue matrix (Gjorevski and Nelson, 2011). The cyto-
kines IL-4, IL-5, and IL-13, the epithelial growth factor amphire-
gulin, and eosinophil and AAM infiltration are all necessary for
normal ductal outgrowth (Aupperlee et al., 2014; Colbert et al.,
2005; Khaled et al., 2007); all of these findings are consistent
with a role for ILC2s, which promote adipose tissue eosinophils
and AAM (Molofsky et al., 2013b), produce a majority of tissue
IL-5 and IL-13 (Nussbaum et al., 2013), and are a source of am-
phiregulin (Monticelli et al., 2011). Definitive studies, including
the potential role of mammary gland IL-33, ILC2s, and Tregs,
are needed.
Central Nervous System
Prenatally, IL-33 is expressed in discrete regions of the central
nervous system (CNS), including eye and spinal cord (Molofsky
et al., 2013a; Pichery et al., 2012) and postnatally in the thalamus,
cerebellum, spinal cord, and optic nerve (Hudson et al., 2008;
Pichery et al., 2012; Wicher et al., 2013; Yasuoka et al., 2011).
IL-33 is abundant in macroglia, including gray-matter astrocytes
and oligodendrocytes (Hudson et al., 2008; Yasuoka et al., 2011).
Microglia, the primary immune cells of the CNS, can express ST2
and are positioned to respond to glial signals (Yasuoka et al.,
2011). In models of CNS damage, IL-33 promotes microglial
and macrophage alternative activation and limits glial scarring
(Luo et al., 2015; Pomeshchik et al., 2015). Astrocytes andmicro-
glia also participate in neural circuit formation during develop-
ment, and immunemolecules can fundamentally shape and alter
these circuits (Clarke and Barres, 2013). A role for glial-derived
IL-33 in shaping CNS neural circuits remains unknown.
Despite the widespread constitutive pool of nuclear IL-33 and
strategically positioned ST2-expressing cells, both IL-33-defi-
cient and ST2-deficient mice are grossly normal and suffer no
overt developmental abnormalities. As previously noted, IL-33
is also expressed at barrier surfaces that contact the environ-
ment and commensals, including the skin, lung, and gastrointes-
tinal tract (Pichery et al., 2012). The potential homeostatic func-
tions of IL-33 at these sites and others during normal growth and
development have not been systematically explored.
IL-33 in Type 2 Immune Responses
At the time of its discovery as a cytokine binding to the ST2 re-
ceptor, IL-33 was administered to mice exogenously by a vari-1010 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.ety of routes and methods (Humphreys et al., 2008; Kondo
et al., 2008; Miller et al., 2008; Schmitz et al., 2005). In each
case, massive infiltrations of tissues by eosinophils, epithelial
goblet cell hyperplasia, and elevations of typical type 2 cyto-
kines were noted. These responses also occurred in Rag-defi-
cient mice, indicating that innate cells were the primary target
of IL-33 (Kondo et al., 2008). Importantly, these observations
formed the cornerstone of experiments that later contributed
to the discovery and characterization of ILC2s (Moro et al.,
2010; Neill et al., 2010; Price et al., 2010). As such, these first
experiments revealed that ILC2s are a dominant ST2+ cell
responsive to IL-33 in the intact animal and have prompted
further investigations into the role of IL-33 in type 2 immune
responses that accompany helminth infections, allergy, and
asthma.
IL-33 and Helminth Infection
In the mouse, infection with the helminth Nippostrongylus brasi-
liensis causes IL-33 release (Moro et al., 2010) and activation of
ILC2s (Moro et al., 2010; Neill et al., 2010; Price et al., 2010),
which cooperate with Th2 cells tomediate intestinal worm expul-
sion (Neill et al., 2010; Oliphant et al., 2014; Price et al., 2010).
IL-33 signaling is not absolutely required for the generation of
CD4+ Th2 cells (Hoshino et al., 1999; Townsend et al., 2000),
N. brasiliensis intestinal clearance (Neill et al., 2010; Senn
et al., 2000), or IgE responses (Hung et al., 2013; Townsend
et al., 2000), although it expedites these processes in part via
efficient ILC2 activation (Hung et al., 2013; Neill et al., 2010). Dur-
ing infection with Schistosoma mansoni, IL-33 signaling was
required for optimal granuloma formation, lung eosinophilia,
and Th2 cytokine production (Townsend et al., 2000). IL-33 pro-
motes Th2 cells necessary to clear Trichuris muris (Humphreys
et al., 2008), and IL-33 signaling limited Trichinella spiralis encys-
tation in muscle (Scalfone et al., 2013). IL-33 can cooperate with
other epithelial cytokines, including IL-25 (Neill et al., 2010), to
mediate helminth clearance. In vitro, ILC2s are synergistically
activated by IL-33 when combined with other cytokines such
as IL-2, IL-7, IL-9, and TSLP (Martinez-Gonzalez et al., 2015; Oli-
phant et al., 2014; Turner et al., 2013; Wilhelm et al., 2011), sug-
gesting environmental perturbations are integrated to mediate
these responses. Thus, IL-33 is a partially redundant but impor-
tant component of type 2 immune responses in the context of
helminth infection.
Th1 cell-associated inflammatory responses can counter-
regulate IL-33-associated Th2 cell immunity. Thus, IL-1b can
impair intestinal IL-33 upregulation during helminth infection
and limit the ability to clear chronic gastrointestinal infection
(Zaiss et al., 2013). Similarly, mice lacking the IL-1b receptor,
IL-1R, or the adaptor MyD88, had more robust intestinal granu-
loma formation when infected with Heligmosomoides polygyrus
(Reynolds et al., 2014). In models of cerebral malaria, IL-33
administration protected against Th1 cell-associated lethality
by inducing ILC2s and Tregs (Besnard et al., 2015). IFN-g
potently inhibits IL-33-mediated ILC2 activation in vitro and
in vivo following Listeria infection (Molofsky et al., 2015). IL-33
has been implicated in protection or pathology in a variety of
additional bacterial and parasitic infections, as recently reviewed
(Rostan et al., 2015), although the mechanisms of action in these
models are not well defined.
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Large-scale GWASs implicate both IL33 and IL1RL1 in suscep-
tibility to asthma; other loci associated with ILC2 and Th2 cell
function, including IL13, TSLP, and RORA were also noted
(Gudbjartsson et al., 2009; Moffatt et al., 2010; Torgerson
et al., 2011). IL-33 was required for ovalbumin- and papain-
induced type 2 airway inflammation (Oboki et al., 2010). Addi-
tional allergic challenges, including Alternaria (Bartemes et al.,
2012; Kouzaki et al., 2011; Snelgrove et al., 2014), house dust
mite extract (Willart et al., 2012), and chitin polymers (Van Dyken
et al., 2014) were found to induce lung IL-33 that promoted Th2
immune responses and airway hyperreactivity. IL-33 induction
occurred in both hematopoietic and non-hematopoietic cells,
particularly in alveolar type 2 cells (Kouzaki et al., 2011;McSorley
et al., 2014; R.M.L., unpublished data). Activation of lung ILC2s
(Bartemes et al., 2012; Beamer et al., 2013; Doherty et al.,
2012; Halim et al., 2012; Van Dyken et al., 2014), Th2 cells
(Endo et al., 2015; Kurowska-Stolarska et al., 2008), or both
(Iijima et al., 2014), were required to mediate the allergic pheno-
type, depending on the model system. ILC2s might indirectly
support the generation of Th2 cells via IL-13 induction of den-
dritic cell migration or through direct ILC2/Th2 interactions
(Halim et al., 2014; Martinez-Gonzalez et al., 2015; Oliphant
et al., 2014). Additionally, Th2 and Th9 cells produce gc recep-
tor-binding cytokines such as IL-2, IL-4, and IL-9, which can
potentiate ILC2 activation (Mirchandani et al., 2014; Wilhelm
et al., 2011). IL-33 can also act directly on ST2+ Th2 cells
in vitro (Guo et al., 2009; Schmitz et al., 2005) and in vivo
(Endo et al., 2015; Kurowska-Stolarska et al., 2008) to promote
cytokine production.
IL-33 plays a role in other models of allergic disease, including
allergic rhinitis and chronic rhinosinusitus through activation of
ILC2s, basophils, and mast cells (Haenuki et al., 2012; Kato,
2015; Mjo¨sberg et al., 2011; Nakanishi et al., 2013). In humans,
chronic eosinophilic rhinosinusitis with nasal polyps is associ-
ated with increased epithelial IL-33 and IL-13+ ILC2s (Shaw
et al., 2013). IL-33 is expressed in skin keratinocytes and is
elevated in humans and mouse models of atopic dermatitis
(Kim and Artis, 2015). In mice, overexpression of IL-33 in the
skin can cause atopic dermatitis-like immune pathology (Imai
et al., 2013). The role of endogenous IL-33 in murine atopic
dermatitis models has been inconsistent (Kim et al., 2013; Salimi
et al., 2013), suggesting that IL-33 might be one of several sig-
nals that together promote disease (Kim and Artis, 2015). IL-33
might contribute to gastrointestinal food allergy (Chu et al.,
2013; Muto et al., 2014) and other eosinophilic gastrointestinal
diseases, although further study is required to delineate these
roles. Together, these findings indicate that IL-33 can promote
pathologic type 2 immune responses, particularly at barrier
surfaces such as the lung and skin. Similar to helminth infections,
IL-33 frequently acts in combination with additional signals such
as IL-2, IL-9, TSLP, IL-25, leukotrienes, prostaglandins, or TL1A,
to promote ILC2 and/or Th2 functions (vonMoltke and Locksley,
2014). Inhibition of the IL-33 pathway might be a promising ther-
apeutic approach for limiting these pathologic responses (Fahy,
2015).
IL-33 promotes both protective and pathologic type 2 immune
responses in the setting of tissue injury (Figure 2B), which might
represent extensions of the role of IL-33 during tissue homeosta-sis, here termed ‘‘amplification.’’ Indeed, type 2 immunity plays
active roles in bothwound healing and helminth immunity (Gause
et al., 2013). Helminths induce adaptive Th2 cells and low-affinity
IgE antibody production, but these responses typically cause
little acute tissue pathology, likely due to the concomitant
activation of regulatory cells, such as Treg (Finlay et al., 2014;
McSorley and Maizels, 2012). Although helminths actively
elicit regulatory responses in part through secretion of im-
mune-modulatory products (Finlay et al., 2014; McSorley and
Maizels, 2012), IL-33 itself has direct and indirect effects in stim-
ulating these regulatory pathways (Molofsky et al., 2015). In
contrast, allergic pathologic states are characterized by chronic
elevations in tissue IL-33 and activated ILC2s with Th2 cells and
are associated with tissue pathology and a failure to activate or
maintain regulatory responses, including Treg. In these chronic
settings, Th2 cells likely become activated during repetitive
rounds of antigenic stimulation, further driving maladaptive
cycles of immune dysfunction.
IL-33 in Tissue Damage, Repair, and Fibrosis
Work in models of cardiovascular disease demonstrated IL-33
induction following vascular and cardiac stress that was corre-
lated with improved outcomes (Miller et al., 2008; Onda et al.,
1999; Sanada et al., 2007; Sa´nchez-Ma´s et al., 2014). IL-33
reduced atherosclerosis (Miller et al., 2008), limited pressure
overload-induced cardiac hypertrophy (Sanada et al., 2007),
and improved cardiac function and cardiomyocyte survival after
myocardial infarction (Seki et al., 2009). IL-33 administration ex-
pands ILC2s and Tregs and protects in models of allograft rejec-
tion, tissue injury, and pathology driven by excess type 1 immune
responses (Brunner et al., 2011; Duan et al., 2012; Liang et al.,
2013; Schiering et al., 2014; Turnquist et al., 2011; Yin et al.,
2013). ST2+ Tregs are also increased during helminth infection
(Layland et al., 2010; Molofsky et al., 2015) and in models of
muscle damage (Burzyn et al., 2013), suggesting that damage-
induced IL-33 might participate in these responses. However,
elevated serum IL-33 can also be associated with autoimmune
disease and chronic pathology (Palmer and Gabay, 2011). Hu-
man patients with systemic sclerosis have elevated IL-33 levels
that correlated with the extent of skin and lung fibrosis (Yanaba
et al., 2011). In mouse models of liver damage, IL-33 activates
ILC2s to expand, produce IL-13 and promote hepatic stellate
cell activation and liver fibrosis (McHedlidze et al., 2013). IL-33
can also cause skin fibrosis in an ILC2- and eosinophil-depen-
dent manner (Rankin et al., 2010). These findings suggest IL-33
promotes tissue repair, likely coordinated by ILC2s and Tregs,
but that these pathways can become maladaptive when chronic
or excessive, resulting in allergic pathology and fibrosis. These
changes might reflect the outgrowth of pathologic Th2 effector
cells, loss of regulatory cells, and/or damage or depletion of tis-
sue niches for critical precursor cells required to sustain tissue
homeostasis.
IL-33-ST2 in Infection and Non-Allergic Inflammation
During inflammatory, infectious, and neoplastic insults, other
white blood cells, including neutrophils, macrophages, NK cells,
NKT cells, Th1 cells, and CD8+ T cells, are recruited to damaged
tissues and gain responsiveness to IL-33, a process we term
‘‘conversion’’ (Figure 2C). These cells express little ST2 at rest,Immunity 42, June 16, 2015 ª2015 Elsevier Inc. 1011
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cytes, can be induced in response to signals such as IL-12 (Bour-
geois et al., 2009; Smithgall et al., 2008; Sun et al., 2009; Yang
et al., 2011). Th1 cells required STAT4 signaling and the Th1-
associated transcription factor Tbet to induce transient upregu-
lation of ST2 (Baumann et al., 2015). In these inflammatory
settings, IL-33 drives cell expansion and IFN-g production and
is required for optimal protection against viral infection (Bonilla
et al., 2012; Nabekura et al., 2015; Villarreal and Weiner, 2014).
After immune stimulation, dendritic cells (DCs), which reside
near high endothelial venules (HEVs) in lymphoid organs, are
major sources of IL-12 (Reinhardt et al., 2006). Inflammatory
DCs also interact with fibroblastic reticular cells (FRCs), which
mediate lymph node remodeling and enlargement during infec-
tion (Acton et al., 2014). HEVs and FRCs are primary sources
of lymph node IL-33 in mice and humans (Moussion et al.,
2008; Pichery et al., 2012), and release of IL-33 in these cells
might reflect mechanical forces inherent in the rapid inflamma-
tion-induced changes in lymph node size, akin to findings in
fibroblasts (Kakkar et al., 2012). In contrast, ILC2s, mast cells,
and ST2+ Tregs are rare in lymphoid tissues (Molofsky et al.,
2015; Nussbaum et al., 2013), potentially limiting competition
for IL-33 and allowing IL-12 to drive low amounts of ST2 expres-
sion on inflammatory lymphocytes that enables competence to
detect IL-33. As such, IL-33 might have a role as a vaccine adju-
vant, as revealed in studies in which IL-33 promoted protective
CD4+ and CD8+ T cells against human papilloma virus (Villarreal
et al., 2014). The success of this approach might depend on the
route of the vaccine and its ability to promote a Th1 cell-prone
environment, including IL-12 production (Villarreal and Weiner,
2015).
In mice exposed chronically to tobacco smoke, the IL-33
tissue pool in lung is massively increased and ST2 expression
becomes upregulated on inflammatory leukocytes; in this
setting, IL-33 enhances inflammation and worsens disease
(Kearley et al., 2015). In mouse models of virally driven COPD,
lung precursors increased expression of IL-33; similar findings
were noted in humans with COPD (Byers et al., 2013). These
studies suggest that states of chronic inflammation, such as
COPD, can increase tissue IL-33 pools and IL-33 might coop-
erate with persistent inflammatory signals to further promote
inflammation and tissue damage. There are likely additional sig-
nals that directly repress tissue ILC2s and Tregs during chronic
inflammation (Kearley et al., 2015).
IL-33 has diverse effects in cancer models. Direct overexpres-
sion of IL-33 in neoplasms promoted NK and CD8+ T cell infiltra-
tion and restriction of cancer growth and metastasis (Gao et al.,
2015). However, IL-33 can signal on cancer cells that themselves
express ST2L, thereby promoting survival and metastasis (Kim
et al., 2014; Levescot et al., 2014; Yu et al., 2015). In a model
of breast cancer, exogenous IL-33 drove a mixed regulatory/
type 2 immune infiltrate that promoted tumor growth and metas-
tasis (Jovanovic et al., 2014). Elevated levels of blood ILC2swere
identified in patients with gastric cancer and were associated
with a suppressive immune state (Bie et al., 2014). Together,
the effects of IL-33 on cancer appear context-specific and might
depend on the types of immune cells in the tumor environment,
the amount of available IL-33, the amount of sST2 and the tumor
cell-intrinsic expression of ST2L.1012 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.Integrating the Spectrum of IL-33 Activities
Understanding of IL-33 biology has evolved and expanded from
its predominant role in allergic pathology to unexpected participa-
tion in basic physiologic processes connected with development
and metabolism, to tissue repair and fibrosis, and to roles in
classic inflammation. A framework for conceptualizing the spec-
trum of IL-33 biology hypothesizes a stepwise process by which
the size of the tissue IL-33 nuclear pool, the presence of support-
ing cytokines, and the types of responding cells create a dynamic
element embedded within the functionality of tissues (Figure 3).
Stage 1: Homeostasis
The role of IL-33 during tissue homeostasis is most informed
from studies in adipose tissue, but similar mechanisms might
occur in female reproductive organs and elsewhere (Figure 2A).
At rest, IL-33 is maintained as a reservoir in the nuclei of certain
endothelial and epithelial cells, and perhaps certain fibroblast
reticular stromal cells. In response to poorly defined cues, which
might be mechanical, hormonal, or metabolic, active IL-33 is
translocated to the extracellular space, perhaps through regu-
lated secretion or cellular turnover associated with focal areas
of cell death. The primary targets of constitutive IL-33 production
are likely ILC2s and subsets of Tregs,which are positionedduring
development and whose activation leads to accumulation of
AAMs and eosinophils to create a tissue environment that sup-
presses inflammation andpromotes a reparative state character-
ized by tolerance. At these homeostatic concentrations, effects
of IL-33 are restricted to local tissue by the constitutive presence
of the decoy receptor, sST2, in serum. Similar pathwaysmight be
elicited during localized tissue injury (Brunner et al., 2011; Duan
et al., 2012; Liang et al., 2013; Schiering et al., 2014; Turnquist
et al., 2011; Yin et al., 2013), where the target of these and related
activitiesmight include resident precursor-like stromal cells (Bur-
zyn et al., 2013; Goh et al., 2013; Heredia et al., 2013; Lee et al.,
2015). While speculative at this time, the ability of IL-33, ILC2,
and Treg cells to regulate the tissue regenerative compartment
remains an important area for further study.
Stage 2: Amplification
Migratory helminths, which are highly adapted to their hosts,
elicit the second stage of IL-33 biology characterized by in-
creased numbers and amounts of IL-33 in involved tissues
(Figure 2B). This is accompanied by expansion of ST2+ immune
cells, particularly ILC2s and Th2 cells, which help to restrict
the helminth, but also Treg cells, which repress the pro-inflam-
matory effects of chronic infestation and together promote the
healing of involved tissue. sST2 levels might increase to contain
effects of the expanded IL-33 pool, which can be buffered over
many years before pathologic effects of fibrosis and other tissue
injuries become apparent. Over time, niches for key precursor
cells might become disturbed, such that tissue architecture
can no longer be sustained. Tissue tolerance and metabolic al-
terations necessary to sustain the massive egg-laying capacity
of long-lived helminths might represent adaptations that have
co-evolved with these parasites, which are widespread among
vertebrates (Finlay et al., 2014; Maizels et al., 2012; McSorley
and Maizels, 2012). During allergic pathology, such as asthma
and atopic dermatitis, expansion of ILC2s becomes dissociated
from Treg stimulation, enabling the activation of adaptive
Figure 3. Spectrum of IL-33 Biology
A model of the spectrum of IL-33 effects on tissue
during beneficial and pathologic immune re-
sponses, with IL-33 cellular pools increasing from
left to right. (Homeostasis, Blue) IL-33 is present
in a restricted subset of cells and cooperates
with unknown signals to maintain tissue integrity,
limit excess inflammation, and promote tissue
adaptation to remodeling and other physiologic
stressors. (Amplification, Purple) During acute
tissue injury and damage, IL-33 synergizes with
other epithelial cytokines and lymphokines to
promote tissue homeostasis and repair (stroke,
myocardial infarction, wounding). Helminths elicit
similar responses. With repetitive tissue damage,
IL-33 pools increase, regulatory mechanisms
are suppressed, inflammation is amplified, and
fibrosis ensues (sclerosis, cirrhosis, allergic dis-
ease). (Conversion, Red) Generation of IL-12 and
other inflammatory signals promotes IL-33 sig-
naling on inflammatory cells that are normally un-
responsive, while repressing type 2-associated
responses. Activation of this pathway promotes
beneficial responses to infection and possibly
vaccination, and might support anti-cancer im-
mune responses in certain settings. With chronic
unresolved inflammation, however, tissue IL-33
increases and ultimately contributes to tissue
damage (COPD, autoimmune diseases).
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development of high-affinity IgE capable of activating mast cells
and basophils. Why Treg cells are poorly induced in allergy to
environmental allergens remains perplexing but might reflect
developmental anomalies related to changes in the early post-
natal environment in westernized countries, the so-called ‘‘hy-
giene’’ hypothesis. As such, further research investigating the
early postnatal development, tissue positioning and differentia-
tion of ILC2s and Treg cells might be particularly informative.
Indeed, perinatal Treg cells might have specialized properties
that endow them with functionalities related to tissue-specific
tolerance (Yang et al., 2015).
Stage 3: Conversion
Inflammatory and infectious conditions associated with loss of
epithelial integrity, microbial invasion at damaged barriers, and
damage to precursor populations define the third stage of IL-33
(Figure 2C). Inflammatory cells such as NK cells, Th1 CD4+Immunity 4T cells, and CD8+ T cells acquire ST2
and thus IL-33 sensitivity in response
to IL-12 and other inflammatory media-
tors, such that classical immune inflam-
matory pathways become engaged, a
process we term ‘‘conversion’’ (Villarreal
and Weiner, 2014). Regulatory and type
2 responses are also actively repressed
by inflammatory signals such as IFN-g
(Molofsky et al., 2015). In certain tissues
(lymph nodes, spleen), a relative lack of
otherwise constitutively ST2+ immune
cells might establish permissive condi-
tions for acquiring responsiveness to
IL-33, which is greatly expanded duringthe amplification of the fibroblastic reticular cell network and
(in human) HEV in the enlarging lymph node. Here, IL-33 be-
comes critical in mediating host defense against damaged bar-
riers in the setting of bacterial or viral infection. In the chronic
phases of inflammation, nuclear pools of IL-33 become greatly
expanded in tissue, such that periodic challenges lead to
massive release of active IL-33 that overwhelms local sST2
levels and systemic effects of IL-33 begin to dominate.
Although such a dramatic shift from type 2-associated to
type 1-associated inflammation seems unusual, IL-18, another
member of the IL-1 family, can mediate similarly disparate re-
sponses (Fabbi et al., 2015; Smith, 2011; Voehringer, 2012).
Expression of novel IL-1 family receptors by cells constitutes
an economical mechanism to rapidly re-direct conserved
signaling networks to alternative effector programs in response
to life-threatening challenges.
Although much of this model remains conjectural, it provides a
framework for organizing the complexities of IL-33 biology while2, June 16, 2015 ª2015 Elsevier Inc. 1013
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Reviewexposing areas in need of further investigation. Details of IL-33
production and access to the extracellular environment, of
sST2 production and regulation, and of factors determining the
expression of ST2 on distinct populations of ILC2s and Treg cells
remain unclear. The precise role of ST2 onmyeloid cells is largely
undefined, and the mechanisms by which IL-12 and potentially
other signals enable the expansion of ST2 expression and
IL-33 responsiveness onto inflammatory cytotoxic cells remain
understudied. The next few years will be marked by further un-
derstanding of the remarkable spectrum of biologic processes
affected by IL-33 and its role in homeostasis, repair, host de-
fense, and immunopathology.
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